MedTrace Logo

Advisor HD Grid Observational Study

NCT03733392 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 379

Last updated 2024-04-16

Study results available
· View outcomes & findings →

Summary

The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of electroanatomical mapping with the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ (hereafter called "HD Grid") and EnSite Precision™ Cardiac Mapping System (SV 2.2 or higher, hereafter called "EnSite Precision") with HD Wave Solution™ voltage mapping (hereafter called "HD Wave Solution") in subjects with persistent atrial fibrillation (PersAF) or ventricular tachycardia (VT) in real-world clinical settings.

Conditions

  • Persistent Atrial Fibrillation
  • Ventricular Tachycardia

Interventions

DEVICE

Advisor HD Grid Mapping Catheter, Sensor Enabled

The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-11
Primary Completion
2021-05-27
Completion
2021-05-27

Countries

  • Australia
  • Austria
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Portugal
  • South Africa
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03733392 on ClinicalTrials.gov